Anti-Cancer/ Oncology API Products
探索 抗癌/抗肿瘤 Products
醋酸阿比特龙
抗癌/抗肿瘤
阿达格拉西布
抗癌/抗肿瘤
阿帕鲁胺（无定型及晶型B）
抗癌/抗肿瘤
阿扎胞苷
抗癌/抗肿瘤
盐酸苯 达莫司汀
抗癌/抗肿瘤
硼替佐米
抗癌/抗肿瘤
卡巴他赛
抗癌/抗肿瘤
苹果酸卡博替 尼
抗癌/抗肿瘤
卡培他滨
抗癌/抗肿瘤
卡非佐米
抗癌/抗肿瘤
达罗他胺
抗癌/抗肿瘤
达沙替尼一水 合物
抗癌/抗肿瘤
地西他滨
抗癌/抗肿瘤
氘可来昔替尼
抗癌/抗肿瘤
呋喹替尼
抗癌/抗肿瘤
盐酸吉西 他滨
抗癌/抗肿瘤
格拉司琼
抗癌/抗肿瘤
来那度胺（晶 型A)
抗癌/抗肿瘤
甲磺酸仑伐替尼（MIBK溶剂化物）
抗癌/抗肿瘤
洛莫司汀
抗癌/抗肿瘤
米哚妥林（无定型及晶型II）
抗癌/抗肿瘤
盐酸尼洛替尼
抗癌/抗肿瘤
奥拉帕利（晶型A）
抗癌/抗肿瘤
哌柏西利（晶型A）
抗癌/抗肿瘤
哌唑帕尼
抗癌/抗肿瘤
培美曲塞二钠七水合物
抗癌/抗肿瘤
吡托布鲁替尼
抗癌/抗肿瘤
泊马度胺
抗癌/抗肿瘤
瑞卢戈利
抗癌/抗肿瘤
瑞普替尼
抗癌/抗肿瘤
图卡替尼
抗癌/抗肿瘤
维奈克拉
抗癌/抗肿瘤
Zanubrutinib
抗癌/抗肿瘤
唑来磷酸
抗癌/抗肿瘤
盐酸卡博替尼
抗癌/抗肿瘤
艾日布林
抗癌/抗肿瘤
恩扎卢胺
抗癌/抗肿瘤
甲苯磺酸利特昔替尼
抗癌/抗肿瘤
甲磺酸仑伐替尼（晶型 C及)
抗癌/抗肿瘤
尼拉帕尼
抗癌/抗肿瘤
Dr. Reddys Portfolio of Anti-cancer APIs
We manufacture our Anti-cancer APIs at cGMP API manufacturing facilities which are successfully inspected by international regulatory authorities such as the USFDA, EMEA, ANVISA, PMDA, and Health Canada.
Our team of process experts draws on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design, the process is lean, free from potential genotoxic impurities, and scalable to manufacture for early market entries. This is of particular importance to select the optimal synthesis route in the context of the IP situation. Other aspects are the solid-state forms and particle characteristics that are critical in formulation development.
We have incorporated sensitive and rigorous analytical methods to control the impurities at a specified level and extensively studied the flow properties, crystal size/shape, and morphology in accordance with future requirements. In addition, our APIs have been designed to address customized PSD requirements through size reduction and crystallization techniques, resulting in a high probability of successful formulation development.
USPs of our Anti-cancer APIs
- QbD approach for an efficient process & high-quality output
- Availability of APIs in various forms.
- cGMP API manufacturing facility - Successfully inspected by international regulatory authorities.
- GTIs & impurities are controlled below the TTC limit & ICH limits, respectively.
- Formulation dossier filed across all major markets.
- Regulatory filing available across the globe.
- Completely backward integrated on the Key starting materials to ensure uninterrupted supplies.
- Adequate capacity to meet the global demands.
- KSM suppliers with timely deliveries and adherence to stringent specifications.
- Process safety management guidelines are implemented to enable a sustainable product supply.
- IP-Compliant API that meets regulatory requirements.
Dr. Reddy, is well-positioned to meet the global demand for Anti-cancer/Oncology APIs. As for many of our APIs. the key starting materials (KW) are backward integrated today. We've also established strategic solid sourcing and logistics partnerships and work closely with our customers to successfully manage Me capacities of our manufacturing units ahead of launches.
To know more about our end-to-end solutions for Anti-cancer/Oncology APIs formulations and Dosage forms. Check out our board portfolio of Anti-cancer/Oncology APIs here (Link) (or) Contact us at [email protected]
探索 other Therapeutic categories.
Category-Oncology FAQ
- The oncology API market aims to share and reshape the flow of the pharmaceutical industry's demand.
- The global oncology API market is expected to exhibit strong growth from 2022 to 2026.
- The cancer API Market is expected to reach USD 1,48,545.23 Million by 2030 at 7.10% CAGR during the forecast period 2022-2030.
Oncology drugs are therapeutics used to treat cancer, a group of diseases caused by uncontrolled growth and division of abnormal cells. Oncology drugs include a range of different types of medications, such as chemotherapy agents, targeted therapies, immunotherapies, and hormone therapies.
- Thalidomide Analogues
- Alkalyting agents
- Androgen receptors
- Folate Analog Metabolic
- Nucleoside
- Metabolic
- Microtubule
Alkylating agents - cross-linking of DNA strands, inhibiting DNA replication and RNA transcription. Some antimetabolites - Interfere with DNA or RNA synthesis. Alkaloids bind to tubulin and inhibit the formation of microtubules, causing metaphase arrest, and camptothecins inhibit topoisomerase. Others - induces cell death or differentiation.
The knock of the API sector is having a significant effect on the overall cancer API market growth. The Oncology API market has undergone immense changes due to supply chain disruption caused by COVID-19. COVID-19 has disrupted the pharmaceutical industry's production and supply chain.
The global oncology drugs market size was valued at 135.4 Billion in 2020 and is projected to reach 274.4 billion by 2030, registering a CAGR of 7.5% from 2021 to 2030.
免责声明
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。